BIBW2992(Afatinib) --- EGFR Inhibitor

Catalog No. size PriceQuantity
M60065-5S 5 mg solid $109
M60065-50S 50mg solid $590


BIBW2992 (Afatinib) is a highly potent and selective irreversible EGFR inhibitor, inhibiting EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM, 14 nM, respectively. BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines, exhibits potent effects on both EGFR and HER2 phosphorylation, and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib. BIBW2992 is currently undergoing Phase III clinical trials for non-small cell lung carcinoma (NSCLC) and breast cancer.

Product information

CAS Number: 439081-18-2

Molecular Weight: 485.94

Formula: C24H25ClFN5O3

Chemical Name: (S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide

Smiles: CN(C)C/C=C/C(=O)NC1=CC2=C(NC3=CC(Cl)=C(F)C=C3)N=CN=C2C=C1O[C@@H]1COCC1


InChi: InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO up to 100 mM

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

BIBW2992 was used at 1-10 µM final concentration in vitro and in cellular assays.

In Vivo:

BIBW2992 was orally dosed to mice at 20 mg/kg once per day, or in combination with 2 mg/kg of Rapamycin to significantly reduce the tumor volume. Formulation: 0.5% methylcellulose/0.4% Tween-80.


  1. Li D, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. (2008) Oncogene. 27(34):4702-11.
  2. Perera SA, et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. (2009) Proc Natl Acad Sci U S A. 106(2):474-9.
  3. Khelwatty SA, et al. Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. (2011) Int J Oncol. 39(2):483-91.
  4. Solca F, et al. Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker. (2012) J Pharmacol Exp Ther. 343(2):342-50.

Products are for research use only. Not for human use.


Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed